Literature DB >> 1661613

Investigating the presence of HIV sequences and the distribution of virological markers in hemophiliacs and their sexual partners.

M da S Cardoso1, S Epple, K Koerner, B Kubanek, D Ellbrück, E Seifried.   

Abstract

In this study, we report the investigation of a hemophiliac cohort, in which the last HIV-1 seroconversion occurred in 1985. We wanted to evaluate whether 5 years later the results of serological screening and polymerase chain reaction (PCR) technology would match. We examined 61 German patients with congenital deficiencies of factors VII, VIII-c, and IX, and 16 sexual partners (15 partners of anti-HIV-1-negative hemophiliacs). Patients' and partners' anti-HIV-1 status was determined by ELISA and Western blot. Further, we applied the PCR to investigate the possible presence of HIV sequences in anti-HIV-1-negative individuals. Four sets of primers were used in four separated reactions to avoid false-negative results due to genetic variation, as well as false-positive results due to DNA carryover. The data by PCR were not different from the data attained by conventional serological methods. The prevalence of serological markers for HBV and HCV was determined.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661613     DOI: 10.1007/bf01709653

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  24 in total

1.  Identification of HIV-infected seronegative individuals by a direct diagnostic test based on hybridisation to amplified viral DNA.

Authors:  M Loche; B Mach
Journal:  Lancet       Date:  1988-08-20       Impact factor: 79.321

2.  Avoidance of PCR false positives [corrected].

Authors:  P A Kitchin; Z Szotyori; C Fromholc; N Almond
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods.

Authors:  D T Imagawa; M H Lee; S M Wolinsky; K Sano; F Morales; S Kwok; J J Sninsky; P G Nishanian; J Giorgi; J L Fahey
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

6.  Increase in prevalence of anti-HTLV-III in haemophiliacs.

Authors:  L G Gürtler; D Wernicke; J Eberle; G Zoulek; F Deinhardt; W Schramm
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

7.  DNA amplification of HIV-1 in seropositive individuals and in seronegative at-risk individuals.

Authors:  M Mariotti; J J Lefrère; B Noel; F Ferrer-Le-Coeur; D Vittecoq; R Girot; C Bosser; A M Couroucé; C Salmon; P Rouger
Journal:  AIDS       Date:  1990-07       Impact factor: 4.177

8.  Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs.

Authors:  W Schramm; M Roggendorf; F Rommel; R Kammerer; H Pohlmann; R Rasshofer; L Gürtler; F Deinhardt
Journal:  Blut       Date:  1989-10

9.  1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B.

Authors:  M V Ragni; A Winkelstein; L Kingsley; J A Spero; J H Lewis
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

10.  Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV).

Authors:  S Harada; N Kobayashi; Y Koyanagi; N Yamamoto
Journal:  Virology       Date:  1987-06       Impact factor: 3.616

View more
  1 in total

1.  Prevalence of HCV-RNA-positive blood donors and correlation to ELISA and RIBA status.

Authors:  M da Silva Cardoso; K Koerner; S Epple; B Kubanek
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.